$MBOT
Microbot Medical Inc. Stock $mbot

$mbot Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000119312514199109 Filed on May 14, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$23.00K	$24.00K	$56.00K
YoY Change	-30.3%	-57.14%	-91.3%
Cost Of Revenue	$78.10K	$87.28K	$66.84K
YoY Change	0.68%	30.57%	-7.17%
Gross Profit	$164.1K	$252.2K	$217.4K
YoY Change	-19.6%	16.03%	-62.0%
Gross Profit Margin	713.51%	1050.85%	388.14%
Selling, General & Admin	$2.176M	$2.248M	$1.888M
YoY Change	37.58%	19.06%	-1.68%
% of Gross Profit	1325.84%	891.18%	868.5%
Research & Development	$5.839M	$4.630M	$4.564M
YoY Change	21.53%	1.44%	15.83%
% of Gross Profit	3558.24%	1835.69%	2099.7%
Depreciation & Amortization	$330.0K	$335.9K	$239.6K
YoY Change	43.48%	40.2%	-11.28%
% of Gross Profit	201.09%	133.17%	110.21%
Operating Expenses	$7.983M	$6.866M	$6.165M
YoY Change	30.21%	11.37%	4.53%
Operating Profit	-$7.960M	-$6.842M	-$6.257M
YoY Change	27.94%	9.35%	17.48%
Interest Expense	$343.2K	$380.5K	$10.15K
YoY Change	-12.63%	3649.39%	-100.21%
% of Operating Profit
Other Income/Expense, Net	-$4.011M	-$720.4K	-$159.3K
YoY Change	-1237.67%	352.24%	-96.75%
Pretax Income	-$11.95M	-$7.590M	-$6.420M
YoY Change	103.58%	18.22%	-37.24%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$12.12M	-$7.620M	-$6.416M
YoY Change	106.44%	18.76%	-37.27%
Net Earnings / Revenue	-52674.89%	-31751.07%	-11457.94%
Basic Earnings Per Share
Diluted Earnings Per Share	-$403.0M	-$254.7M	-$321.0M
COMMON SHARES
Basic Shares Outstanding	55.51M shares	55.42M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.85M	$26.46M	$17.05M
YoY Change	-26.18%	55.19%	46.98%
Cash & Equivalents	$17.85M	$26.46M	$7.231M
Short-Term Investments			$9.820M
Other Short-Term Assets	$107.4K	$83.70K	$1.250M
YoY Change	-84.75%	-93.3%	204.88%
Inventory
Prepaid Expenses	$690.2K	$413.4K
Receivables	$88.04K	$100.4K	$60.00K
Other Receivables	$130.0K	$110.0K	$250.0K
Total Short-Term Assets	$18.90M	$27.21M	$18.61M
YoY Change	-27.29%	46.23%	50.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.141M	$5.275M	$1.520M
YoY Change	48.99%	247.01%	-17.84%
Goodwill	$2.208M	$2.147M
YoY Change	19.01%
Intangibles	$1.727M	$1.766M
YoY Change	4.39%
Long-Term Investments
YoY Change
Other Assets	$373.7K	$413.7K	$1.060M
YoY Change	-64.54%	-60.97%	-41.44%
Total Long-Term Assets	$9.458M	$9.617M	$6.150M
YoY Change	17.39%	56.37%	-19.08%
TOTAL ASSETS
Total Short-Term Assets	$18.90M	$27.21M	$18.61M
Total Long-Term Assets	$9.458M	$9.617M	$6.150M
Total Assets	$28.36M	$36.83M	$24.76M
YoY Change	-16.72%	48.75%	24.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.706M	$2.190M	$1.430M
YoY Change	-43.54%	53.17%	53.76%
Accrued Expenses	$2.613M	$2.231M	$2.050M
YoY Change	36.26%	8.82%	-39.35%
Deferred Revenue
YoY Change
Short-Term Debt	$3.830M	$3.750M	$0.00
YoY Change	46.74%
Long-Term Debt Due	$17.92K	$71.25K	$220.0K
YoY Change	-91.62%	-67.61%	10.0%
Total Short-Term Liabilities	$8.296M	$8.370M	$3.740M
YoY Change	6.07%	123.79%	-17.8%
LONG-TERM LIABILITIES
Long-Term Debt	$11.13M	$12.12M	$80.00K
YoY Change	63500.0%	15050.0%	-71.43%
Other Long-Term Liabilities	$11.48M	$8.680M	$10.73M
YoY Change	9.65%	-19.11%	-18.15%
Total Long-Term Liabilities	$22.61M	$20.80M	$10.81M
YoY Change	129100.0%	92.41%	-19.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.296M	$8.370M	$3.740M
Total Long-Term Liabilities	$22.61M	$20.80M	$10.81M
Total Liabilities	$30.90M	$29.17M	$14.56M
YoY Change	22.18%	100.36%	-18.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$407.3M	-$395.2M
YoY Change	9.08%
Common Stock	$404.4M	$402.5M
YoY Change	5.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.543M	$7.658M	$10.21M
YoY Change
Total Liabilities & Shareholders Equity	$28.36M	$36.83M	$24.76M
YoY Change	-16.72%	48.75%	24.17%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$12.12M	-$7.620M	-$6.416M
YoY Change	106.44%	18.76%	-37.27%
Depreciation, Depletion And Amortization	$330.0K	$335.9K	$239.6K
YoY Change	43.48%	40.2%	-11.28%
Cash From Operating Activities	-$7.770M	-$6.508M	-$6.652M
YoY Change	105.56%	-2.17%	18.15%
INVESTING ACTIVITIES
Capital Expenditures	-$130.0K	$230.7K	$319.9K
YoY Change	-93.81%	-27.89%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$4.020M
YoY Change		-100.0%	252.63%
Cash From Investing Activities	-$130.0K	-$230.7K	$3.703M
YoY Change	-102.07%	-106.23%	227.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.568M
YoY Change
Debt Paid & Issued, Net		$998.1K
YoY Change
Cash From Financing Activities	-720.0K	2.616M	1.716M
YoY Change	-105.54%	52.45%	163.94%
NET CHANGE
Cash From Operating Activities	-7.770M	-6.508M	-6.652M
Cash From Investing Activities	-130.0K	-230.7K	3.703M
Cash From Financing Activities	-720.0K	2.616M	1.716M
Net Change In Cash	-8.620M	-4.123M	-1.233M
YoY Change	-155.58%	234.3%	-67.97%
FREE CASH FLOW
Cash From Operating Activities	-$7.770M	-$6.508M	-$6.652M
Capital Expenditures	-$130.0K	$230.7K	$319.9K
Free Cash Flow	-$7.640M	-$6.738M	-$6.972M
YoY Change	354.76%	-3.35%	23.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2009Q1	stem	Business Acquisition Cost Of Acquired Entity Purchase Price Net BusinessAcquisitionCostOfAcquiredEntityPurchasePriceNet	5135000
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7231078
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55419116	shares
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8369773
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55514404	shares
CY2009Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	5135000
CY2009Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	36000
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55419116	shares
CY2014Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.06	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.05
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	381851	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	9551378	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Loans Payable Current LoansPayableCurrent	3747236
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2230808
CY2014Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	21704
CY2014Q1	us-gaap	Loans Payable LoansPayable	15843919
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2190342
CY2014Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	12096683
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	265561
CY2014Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	23848
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	7657809
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	401988647
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-395150590
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	61202
CY2014Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	654961
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2133397
CY2014Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1782654
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	554191
CY2014Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	47231
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36830137
CY2014Q1	us-gaap	Liabilities Liabilities	29172328
CY2014Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	58704
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	71250
CY2014Q1	us-gaap	Assets Current AssetsCurrent	27213592
CY2014Q1	us-gaap	Goodwill Goodwill	2147426
CY2014Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	26463625
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1765658
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	413717
CY2014Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	413416
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	300434
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	80851
CY2014Q1	us-gaap	Assets Assets	36830137
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26463625
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	100388
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	242588
CY2014Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	40496
CY2014Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	100000
CY2014Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4203612
CY2014Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	15144
CY2014Q1	us-gaap	Other Assets Current OtherAssetsCurrent	83702
CY2014Q1	us-gaap	Other Receivables OtherReceivables	111965
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	215639
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	195066
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3677000
CY2014Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	26463625
CY2014Q1	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	944339
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5274600
CY2014Q1	stem	Carrying Value Of Purchased Loans CarryingValueOfPurchasedLoans	9512000
CY2014Q1	stem	Fair Value Of Warrant Liability FairValueOfWarrantLiability	5868433
CY2014Q1	stem	Fair Value Allocated To Warrant FairValueAllocatedToWarrant	388000
CY2014Q1	stem	Deposits And Other Long Term Liabilities DepositsAndOtherLongTermLiabilities	972233
CY2014Q1	stem	Accretion Of Debt Discount Net Carrying Amount AccretionOfDebtDiscountNetCarryingAmount	58750
CY2014Q1	stem	Outstanding Principal Amount Of Long Term Debt OutstandingPrincipalAmountOfLongTermDebt	71250
CY2014Q1	stem	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
CY2014Q1	stem	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
CY2011Q4	stem	Impairments Of Intangible Asset Finite Lived ImpairmentsOfIntangibleAssetFiniteLived	655000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8471275
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55138311	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55138311	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.97
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	428258	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Loans Payable Current LoansPayableCurrent	3664370
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4067916
CY2013Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	29422
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	14953712
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	401680562
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-387530334
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	21316
CY2013Q4	us-gaap	Loans Payable LoansPayable	12909244
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1151903
CY2013Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	9244874
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9132116
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	252101
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	67245
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1790943
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	551383
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	34366
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41557174
CY2013Q4	us-gaap	Liabilities Liabilities	26603462
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	62910
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	125000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	31840455
CY2013Q4	us-gaap	Goodwill Goodwill	2139294
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	30585424
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1835717
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	413717
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	530037
CY2013Q4	us-gaap	Assets Assets	41557174
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30585424
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	108815
CY2013Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	46420
CY2013Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	23307
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	83537
CY2013Q4	us-gaap	Other Receivables OtherReceivables	486222
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	30585424
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5304684
CY2013Q4	stem	Fair Value Of Warrant Liability FairValueOfWarrantLiability	5541809
CY2013Q4	stem	Deposits And Other Long Term Liabilities DepositsAndOtherLongTermLiabilities	801388
CY2013Q4	stem	Outstanding Principal Amount Of Long Term Debt OutstandingPrincipalAmountOfLongTermDebt	125000
CY2013Q4	stem	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
CY2013Q4	stem	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
CY2006Q3	stem	Number Of Patients Violate Claims NumberOfPatientsViolateClaims	4	Claim
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38263434	shares
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6652063
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11282286	shares
CY2013Q1	us-gaap	Revenues Revenues	284200
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-97752
CY2013Q1	us-gaap	Gross Profit GrossProfit	217359
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-6649112
CY2013Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	471392
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	208558
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	32609
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	6846
CY2013Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	112386
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6257147
CY2013Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	38500
CY2013Q1	us-gaap	Interest Paid InterestPaid	10148
CY2013Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	248589
CY2013Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-234104
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-41601
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-159300
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-6416447
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1676
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-232665
CY2013Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	100000
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	319915
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1439
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-798212
CY2013Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	188607
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1715628
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	66841
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-28399
CY2013Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	447715
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	686582
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1233242
CY2013Q1	us-gaap	Interest Expense InterestExpense	10148
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1568178
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	38500
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3703193
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4563890
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	239550
CY2013Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	50000
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	686582
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4556000
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	6474506
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1887757
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-6955
CY2013Q1	stem	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	15575
CY2013Q1	stem	Increase Decrease In Accrued Interest And Other Receivables IncreaseDecreaseInAccruedInterestAndOtherReceivables	53784
CY2013Q1	stem	Share Based Compensation Impact On Basic And Diluted Earnings Per Share ShareBasedCompensationImpactOnBasicAndDilutedEarningsPerShare	0.02
CY2013Q1	stem	Increase Decrease In Accrued Wind Down Expenses IncreaseDecreaseInAccruedWindDownExpenses	474002
CY2013Q1	stem	Wind Down Expenses WindDownExpenses	22859
CY2013Q1	stem	Revenue From Licensing Agreements And Grants RevenueFromLicensingAgreementsAndGrants	75642
CY2014Q1	dei	Trading Symbol TradingSymbol	STEM
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	STEMCELLS INC
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000883975
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	35.81
CY2014Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P3Y
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55343877	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6507546
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2014Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2014Q1	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y2M12D
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	46407	shares
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19794450	shares
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results could differ materially from these estimates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Significant estimates include the following:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="1%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">the grant date fair value of stock-based awards recognized as compensation expense (see Note 5, “Stock-Based Compensation”);</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="1%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">the fair value of warrants recorded as a liability (see Note 8, “Warrant Liability”); and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="1%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">the fair value of goodwill and other intangible assets (see Note 4, “Goodwill and Other Intangible Assets”).</td> </tr> </table> </div>
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-7606796
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	315896
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15639
CY2014Q1	us-gaap	Revenues Revenues	339480
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-102895
CY2014Q1	us-gaap	Gross Profit GrossProfit	252204
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2185
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6899690
CY2014Q1	us-gaap	Interest Paid InterestPaid	141249
CY2014Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	201462
CY2014Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	13460
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8662
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-720566
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-7620256
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5186
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	13460
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	230689
CY2014Q1	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	9900000
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-637190
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	326624
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2615527
CY2014Q1	us-gaap	Proceeds From Loans ProceedsFromLoans	3820264
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	87276
CY2014Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3820264
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-10340
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	521106
CY2014Q1	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	8132
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4122708
CY2014Q1	us-gaap	Debt Issuance Costs DebtIssuanceCosts	117000
CY2014Q1	us-gaap	Interest Expense InterestExpense	380488
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-230689
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4904294
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	335855
CY2014Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5000000
CY2014Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	75000
CY2014Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	998089
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	521106
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	7151894
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2247600
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	909
CY2014Q1	stem	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	4576
CY2014Q1	stem	Loan Fees LoanFees	1000000
CY2014Q1	stem	Number Of Restricted Unit Would Vest Over Vesting Period NumberOfRestrictedUnitWouldVestOverVestingPeriod	376000	shares
CY2014Q1	stem	Warrants Issued Per Unit WarrantsIssuedPerUnit	1
CY2014Q1	stem	Cash And Cash Equivalents Maturity Period CashAndCashEquivalentsMaturityPeriod	P90D
CY2014Q1	stem	Increase Decrease In Accrued Interest And Other Receivables IncreaseDecreaseInAccruedInterestAndOtherReceivables	-387686
CY2014Q1	stem	Restricted Stock Units Vested Description After Specified Period RestrictedStockUnitsVestedDescriptionAfterSpecifiedPeriod	25	pure
CY2014Q1	stem	Number Of Restricted Unit Vest Over Next Fiscal Year NumberOfRestrictedUnitVestOverNextFiscalYear	218874	shares
CY2014Q1	stem	Share Based Compensation Impact On Basic And Diluted Earnings Per Share ShareBasedCompensationImpactOnBasicAndDilutedEarningsPerShare	0.01
CY2014Q1	stem	Long Term Debt Bond Interest Rate LongTermDebtBondInterestRate	0.095	pure
CY2014Q1	stem	Debt Instrument Amortized Discount Percentage DebtInstrumentAmortizedDiscountPercentage	0.090	pure
CY2014Q1	stem	Restricted Stock Unit Conversion Into Shares Period RestrictedStockUnitConversionIntoSharesPeriod	P4Y
CY2014Q1	stem	Number Of Share Based Equity Incentive Plan NumberOfShareBasedEquityIncentivePlan	3	Incentive_Plan
CY2014Q1	stem	Finite Lived Intangible Assets Foreign Currency Translation FiniteLivedIntangibleAssetsForeignCurrencyTranslation	-350404
CY2014Q1	stem	Amortization Of Debt Discount And Debt Issuance Costs AmortizationOfDebtDiscountAndDebtIssuanceCosts	72836
CY2014Q1	stem	Continuing Value Of Patent ContinuingValueOfPatent	0
CY2014Q1	stem	Maturity Period Of Long Term Debt MaturityPeriodOfLongTermDebt	2014-08
CY2014Q1	stem	Revenue From Licensing Agreements And Grants RevenueFromLicensingAgreementsAndGrants	23584
CY2014Q1	stem	Common Stock Per Unit CommonStockPerUnit	1
CY2014Q1	stem	Restricted Stock Unit Vest Description RestrictedStockUnitVestDescription	376,000 of these restricted stock units will vest and convert into shares of our common stock over a four year period
CY2014Q1	stem	Debt Instrument Period During Which Loan Is Subject To Interest Only Payments DebtInstrumentPeriodDuringWhichLoanIsSubjectToInterestOnlyPayments	P6M
CY2014Q1	stem	Debt Instrument Period During Which Loan Is Subject To Principal And Interest Payments DebtInstrumentPeriodDuringWhichLoanIsSubjectToPrincipalAndInterestPayments	P30M

Files In Submission

Name	View Source	Status
0001193125-14-199109-index-headers.html	Edgar Link	pending
0001193125-14-199109-index.html	Edgar Link	pending
0001193125-14-199109.txt	Edgar Link	pending
0001193125-14-199109-xbrl.zip	Edgar Link	pending
d719548d10q.htm	Edgar Link	pending
d719548dex311.htm	Edgar Link	pending
d719548dex312.htm	Edgar Link	pending
d719548dex321.htm	Edgar Link	pending
d719548dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stem-20140331.xml	Edgar Link	completed
stem-20140331.xsd	Edgar Link	pending
stem-20140331_cal.xml	Edgar Link	unprocessable
stem-20140331_def.xml	Edgar Link	unprocessable
stem-20140331_lab.xml	Edgar Link	unprocessable
stem-20140331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MBOT
Microbot Medical Inc. Stock $mbot

2014 Q2 Form 10-Q Financial Statement

#000119312514199109 Filed on May 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBOT Microbot Medical Inc. Stock $mbot

2014 Q2 Form 10-Q Financial Statement

#000119312514199109 Filed on May 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBOT
Microbot Medical Inc. Stock $mbot